3 Health Services Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 18 points (0.1%) at 16,551 as of Wednesday, April 2, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,684 issues advancing vs. 1,250 declining with 198 unchanged.

The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.2%. A company within the industry that fell today was Smith & Nephew ( SNN), up 0.7%. A company within the industry that increased today was Intuitive Surgical ( ISRG), up 4.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Humana ( HUM) is one of the companies pushing the Health Services industry lower today. As of noon trading, Humana is down $0.87 (-0.8%) to $112.40 on light volume. Thus far, 557,407 shares of Humana exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $111.92-$113.56 after having opened the day at $113.56 as compared to the previous trading day's close of $113.27.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in Retail, Employer Group, Healthcare Services, and Other Businesses segments. Humana has a market cap of $17.4 billion and is part of the health care sector. Shares are up 9.7% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Humana a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Baxter International ( BAX) is down $0.39 (-0.5%) to $73.28 on light volume. Thus far, 1.2 million shares of Baxter International exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $73.23-$73.64 after having opened the day at $73.64 as compared to the previous trading day's close of $73.67.

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $39.8 billion and is part of the health care sector. Shares are up 5.8% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Baxter International a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Baxter International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, WellPoint ( WLP) is down $1.11 (-1.1%) to $97.98 on light volume. Thus far, 1.1 million shares of WellPoint exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $96.70-$99.26 after having opened the day at $96.70 as compared to the previous trading day's close of $99.09.

WellPoint, Inc., a health benefits company, through its subsidiaries, provides a range of medical products in the United States. The company offers a spectrum of network-based managed care health benefit plans to large and small employer, individual, Medicaid, and senior markets. WellPoint has a market cap of $28.1 billion and is part of the health care sector. Shares are up 7.2% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate WellPoint a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates WellPoint as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full WellPoint Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Why a Walgreens Purchase of Humana or WellCare Now Appears Less Likely

Why a Walgreens Purchase of Humana or WellCare Now Appears Less Likely

Why Centene Is One of Jim Cramer's 'Absolute Favorite Stocks'

Why Centene Is One of Jim Cramer's 'Absolute Favorite Stocks'

Wall Street Volatility, Disney, Snap and Steve Wynn - 5 Things You Must Know

Wall Street Volatility, Disney, Snap and Steve Wynn - 5 Things You Must Know

Investors Are Trying to Figure Out the 'Powell Put'

Investors Are Trying to Figure Out the 'Powell Put'

Bullish Humana Stock Should Keep 'HUM'ming Along

Bullish Humana Stock Should Keep 'HUM'ming Along